




## **FINAL NICE APPRAISAL RECOMMENDS IMPROVED ACCESS TO TREATMENT AND CARE OF PEOPLE WITH EARLY ALZHEIMER'S DISEASE**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that The National Institute for Health and Clinical Excellence (NICE), a special agency of the United Kingdom National Health Service (NHS), has issued final appraisal recommendations regarding the treatment of patients with mild Alzheimer's disease.

The new ruling means Alzheimer's disease patients with mild-to-moderate forms of the disease will have access to treatment with acetylcholinesterase inhibitors (AChEIs), including Aricept<sup>®</sup>. Based on revised

---



**[Notes to editors]**

**1 Additional Information on the NICE Guidance**

**Appraisal Committee Final Recommendations**

1.1 The three acetylcholinesterase (AChE) inhibitors (donepezil, galantamine and rivastigmine) are recommended as options for managing mild to moderate Alzheimer's disease (as per their license indications), under all of the following conditions:

- ' Only specialists in the care of patients with dementia should initiate treatment.
- ' Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional and behavioral symptoms.
- '